5822830
Last Update Posted: 2024-12-11
Recruiting has ended
All Genders accepted | 18 Years + |
751 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Eligibility
Relevant conditions:
Obesity
Overweight
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov